(Q24234846)

title

Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin (English)

0 references

0 references

1

Ayeesha K Kamal

0 references

author name string

Imama Naqvi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6599824&resulttype=core&format=json

15 May 2020

Muhammad R Husain

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6599824&resulttype=core&format=json

15 May 2020

Bhojo A Khealani

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6599824&resulttype=core&format=json

15 May 2020

Ayeesha K Kamal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6599824&resulttype=core&format=json

Cochrane Database of Systematic Reviews

15 May 2020

publication date

19 January 2011

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6599824&resulttype=core&format=json

15 May 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6599824&resulttype=core&format=json

15 May 2020

page(s)

CD008076

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6599824&resulttype=core&format=json

Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study

15 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008076.PUB2

Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008076.PUB2

Decrease in carotid intima media thickness after 1 year of cilostazol treatment in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008076.PUB2

Rationale and protocol of a trial for prevention of diabetic atherosclerosis by using antiplatelet drugs: study of Diabetic Atherosclerosis Prevention by Cilostazol (DAPC study)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008076.PUB2

Effect of cilostazol, a phosphodiesterase inhibitor, on carotid IMT in Japanese type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008076.PUB2

Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008076.PUB2

The mechanisms of action of nonsteroidal antiinflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008076.PUB2

Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008076.PUB2

Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008076.PUB2

Chinese-white differences in the distribution of occlusive cerebrovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008076.PUB2

The effect of cilostazol, a cyclic nucleotide phosphodiesterase III inhibitor, on heparin-binding EGF-like growth factor expression in macrophages and vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008076.PUB2

Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008076.PUB2

Stroke in China: epidemiology, prevention, and management strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008076.PUB2

Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008076.PUB2

Cilostazol in secondary prevention of stroke: impact of the Cilostazol Stroke Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008076.PUB2

Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of monocyte chemoattractant protein-1 in response to tumor necrosis factor-alpha in vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008076.PUB2

Cilostazol for peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008076.PUB2

Risk factor profile and management of cerebrovascular patients in the REACH Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008076.PUB2

Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008076.PUB2

Progression of middle cerebral artery occlusive disease and its relationship with further vascular events after stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008076.PUB2

Cilostazol inhibits the expression of activation-dependent membrane surface glycoprotein on the surface of platelets stimulated in vitro

21 January 2018

1 reference

12 December 2020

Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor

1 reference

12 December 2020

Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction

1 reference

12 December 2020

Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo. Randomized, double-blind cross-over study

1 reference

12 December 2020

Clinical effects of oral cilostazol on suppression of platelet function in patients with cerebrovascular disease

1 reference

12 December 2020

[Antiplatelet therapy in patients with cerebral thrombosis at the chronic phase--assessment of its effect on coagulation and fibrinolytic parameters]

1 reference

12 December 2020

Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo

1 reference

12 December 2020

Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication

1 reference

12 December 2020

10.1002/14651858.CD008076.PUB2

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

3377185

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6599824&resulttype=core&format=json

OpenCitations bibliographic resource ID

15 May 2020

3377185

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6599824&resulttype=core&format=json

15 May 2020

PubMed publication ID

21249700

1 reference